

Sharlene Gill

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8763470/publications.pdf>

Version: 2024-02-01

102
papers

4,829
citations

147726

31
h-index

95218

68
g-index

113
all docs

113
docs citations

113
times ranked

6849
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of Tumor Location on Patient Outcomes in Small Bowel Cancers. <i>Clinical Colorectal Cancer</i> , 2022, 21, 107-113.	1.0	2
2	Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2022, 40, 892-910.	0.8	85
3	Early-Age-Onset Colorectal Cancer in Canada: Evidence, Issues and Calls to Action. <i>Current Oncology</i> , 2022, 29, 3149-3159.	0.9	4
4	Trends in the incidence of young-onset colorectal cancer with a focus on years approaching screening age: A population-based longitudinal study. <i>Journal of the National Cancer Institute</i> , 2021, 113, 863-868.	3.0	14
5	The Impact of Geography in Hepatocellular Carcinoma: A Retrospective Population Based Study. <i>Current Oncology</i> , 2021, 28, 396-404.	0.9	0
6	Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults. <i>Current Oncology</i> , 2021, 28, 523-548.	0.9	31
7	Impact of surveillance among patients with resected pancreatic cancer following adjuvant chemotherapy. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 446-454.	0.6	0
8	Canadian Colorectal Cancer Screening Guidelines: Do They Need an Update Given Changing Incidence and Global Practice Patterns?. <i>Current Oncology</i> , 2021, 28, 1558-1570.	0.9	11
9	Association of Adiponectin and Vitamin D With Tumor Infiltrating Lymphocytes and Survival in Stage III Colon Cancer. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab070.	1.4	4
10	Virtual Oncology Appointments during the Initial Wave of the COVID-19 Pandemic: An International Survey of Patient Perspectives. <i>Current Oncology</i> , 2021, 28, 671-677.	0.9	27
11	Current Attitudes toward Unfunded Cancer Therapies among Canadian Medical Oncologists. <i>Current Oncology</i> , 2021, 28, 4748-4755.	0.9	1
12	Current Oncology: A Multidisciplinary Medium for Clinical Oncology. <i>Current Oncology</i> , 2021, 28, 2-3.	0.9	0
13	A Hypothesis-Generating Study Using Electrophysiology to Examine Cognitive Function in Colon Cancer Patients. <i>Archives of Clinical Neuropsychology</i> , 2020, 35, 226-232.	0.3	2
14	Eligibility for Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 788-791.	0.6	1
15	Efficacy and Prognostic Factors for Y-90 Radioembolization (Y-90) in Metastatic Neuroendocrine Tumors with Liver Metastases. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2020, 2020, 1-5.	0.8	6
16	Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa023.	1.4	36
17	Population-based Screening for <i>BRAF</i> V600E in Metastatic Colorectal Cancer Reveals Increased Prevalence and Poor Prognosis. <i>Clinical Cancer Research</i> , 2020, 26, 4599-4605.	3.2	26
18	Integration of Whole-Genome Sequencing With Circulating Tumor DNA Analysis Captures Clonal Evolution and Tumor Heterogeneity in Non-V600 <i>BRAF</i> Mutant Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2020, 19, 132-136.e3.	1.0	1

#	ARTICLE	IF	CITATIONS
19	Health information seeking behaviors among individuals with young-onset and average-onset colorectal cancer: an international cross-sectional survey. <i>Supportive Care in Cancer</i> , 2020, 28, 6011-6021.	1.0	11
20	Trends in the epidemiology of young-onset colorectal cancer: a worldwide systematic review. <i>BMC Cancer</i> , 2020, 20, 288.	1.1	86
21	Real-world treatment attrition rates in advanced esophagogastric cancer. <i>World Journal of Gastroenterology</i> , 2020, 26, 6027-6036.	1.4	0
22	Current Oncology: A Multidisciplinary Medium for Clinical Oncology. <i>Current Oncology</i> , 2020, 28, 2-3.	0.9	0
23	The Evolving Treatment Landscape of Hepatocellular Carcinoma: More Choices, More Responsibility. <i>Current Oncology</i> , 2020, 27, 136-137.	0.9	1
24	<i>NRG1</i> Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in Wild-Type Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 4674-4681.	3.2	121
25	Translating IDEA to Practice and Beyond: Managing Stage II and III Colon Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 226-235.	1.8	8
26	Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2019, 37, 1436-1447.	0.8	53
27	A phase II trial of the effect of perindopril on hand-foot skin reaction (HFSR) incidence and severity in patients receiving regorafenib for refractory mCRC. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 411-417.	1.1	4
28	Outcomes and Characteristics of Patients Receiving Second-line Therapy for Advanced Pancreatic Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 196-201.	0.6	12
29	Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High-Risk Stage III (pT4) Tumor. <i>Journal of Clinical Oncology</i> , 2019, 37, 1436-1447.	1.0	784314
30	Real-world Outcomes Among Patients Treated With Gemcitabine-based Therapy Post-FOLFIRINOX Failure in Advanced Pancreatic Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 903-908.	0.6	8
31	Survival Impact of CAPOX Versus FOLFOX in the Adjuvant Treatment of Stage III Colon Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, 156-163.	1.0	24
32	Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 263-270.	3.7	121
33	Physical Activity and Outcomes in Patients with Stage III Colon Cancer: A Correlative Analysis of Phase III Trial NCCTG N0147 (Alliance). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 696-703.	1.1	11
34	Utilization of capecitabine plus oxaliplatin and 5-fluorouracil/folinic acid plus oxaliplatin in the adjuvant treatment of stage IIB and stage III colon cancer: A multi-centre, retrospective, chart review study. <i>Journal of Oncology Pharmacy Practice</i> , 2018, 24, 501-506.	0.5	12
35	Beyond the Knife: The Evolving Nonsurgical Management of Oligometastatic Colorectal Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 209-219.	1.8	7
36	Type B lactic acidosis from fluorouracil in fluorouracil, oxaliplatin and leucovorin treatment for carcinoma of the colon in a hemodialysis patient. <i>CKJ: Clinical Kidney Journal</i> , 2018, 11, 786-787.	1.4	4

#	ARTICLE	IF	CITATIONS
37	Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 552-554.	0.6	19
38	Eligibility of Metastatic Pancreatic Cancer Patients for First-Line Palliative Intent nab-Paclitaxel Plus Gemcitabine Versus FOLFIRINOX. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 507-511.	0.6	61
39	Prognostic utility of immune markers and validation of Immunoscore in stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance). <i>Annals of Oncology</i> , 2017, 28, iii153.	0.6	1
40	Survival impact of CAPOX versus FOLFOX in the adjuvant treatment of stage III colon cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 710-710.	0.8	0
41	Determinants of first-line treatment selection in advanced pancreatic ductal adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 468-468.	0.8	1
42	Alcohol consumption and colon cancer prognosis among participants in north central cancer treatment group phase III trial N0147. <i>International Journal of Cancer</i> , 2016, 139, 986-995.	2.3	16
43	Reasons for Underuse of Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer. <i>Clinical Colorectal Cancer</i> , 2016, 15, 179-185.	1.0	38
44	Effects of a Structured Exercise Program on Physical Activity and Fitness in Colon Cancer Survivors: One Year Feasibility Results from the CHALLENGE Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 969-977.	1.1	75
45	Post-gemcitabine therapy for patients with advanced pancreatic cancer – A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens. <i>Cancer Treatment Reviews</i> , 2016, 50, 142-147.	3.4	19
46	Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance). <i>Oncologist</i> , 2016, 21, 1509-1521.	1.9	33
47	PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy. <i>Journal of Clinical Oncology</i> , 2016, 34, 3914-3920.	0.8	210
48	Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer. <i>Cancer</i> , 2015, 121, 527-534.	2.0	118
49	Effect of Adjuvant FOLFOX Chemotherapy Duration on Outcomes of Patients With Stage III Colon Cancer. <i>Clinical Colorectal Cancer</i> , 2015, 14, 262-268.e1.	1.0	17
50	Prognostic Value of Molecular Detection of Lymph Node Metastases After Curative Resection of Stage II Colon Cancer: A Systematic Pooled Data Analysis. <i>Clinical Colorectal Cancer</i> , 2015, 14, 99-105.	1.0	3
51	Effect of Delay in Adjuvant Oxaliplatin-Based Chemotherapy for Stage III Colon Cancer. <i>Clinical Colorectal Cancer</i> , 2015, 14, 25-30.	1.0	14
52	Effect of M1a and M1b Category in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2014, 19, 720-726.	1.9	13
53	Adjuvant therapy for resected high-risk colon cancer: Current standards and controversies. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2014, 35, 197.	0.1	4
54	Molecular Testing for Lymph Node Metastases as a Determinant of Colon Cancer Recurrence: Results from a Retrospective Multicenter Study. <i>Clinical Cancer Research</i> , 2014, 20, 4361-4369.	3.2	18

#	ARTICLE	IF	CITATIONS
55	Comparison of FOLFIRI With or Without Cetuximab in Patients With Resected Stage III Colon Cancer; NCCTG (Alliance) Intergroup Trial N0147. <i>Clinical Colorectal Cancer</i> , 2014, 13, 100-109.	1.0	41
56	Navigating later lines of treatment for advanced colorectal cancer – Optimizing targeted biological therapies to improve outcomes. <i>Cancer Treatment Reviews</i> , 2014, 40, 1171-1181.	3.4	18
57	Update on the Colon Health and Life-Long Exercise Change Trial: A Phase III Study of the Impact of an Exercise Program on Disease-Free Survival in Colon Cancer Survivors. <i>Current Colorectal Cancer Reports</i> , 2014, 10, 321-328.	1.0	26
58	Neutropenia and Relative Dose Intensity on Adjuvant FOLFOX Chemotherapy Are Not Associated with Survival for Resected Colon Cancer. <i>Journal of Gastrointestinal Cancer</i> , 2014, 45, 460-465.	0.6	18
59	Relationship of ethnicity and overall survival in patients treated with sorafenib for advanced hepatocellular carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2014, 5, 259-64.	0.6	10
60	Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma. <i>Cancer</i> , 2013, 119, 380-387.	2.0	93
61	Body Mass Index and Body Surface Area and Their Associations with Outcomes in Stage II and III Colon Cancer. <i>Journal of Gastrointestinal Cancer</i> , 2013, 44, 203-210.	0.6	16
62	Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 1383.	3.8	412
63	Real-world Impact of Availability of Adjuvant Therapy on Outcomes in Patients With Resected Pancreatic Adenocarcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 212-215.	0.6	4
64	A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer. <i>Investigational New Drugs</i> , 2012, 30, 779-786.	1.2	49
65	Evaluation of the prognostic value of guanylyl cyclase C (GCC) lymph node (LN) classification in patients with stage II colon cancer: A pooled analysis. <i>Journal of Clinical Oncology</i> , 2012, 30, 443-443.	0.8	0
66	Survival for Metastatic Colorectal Cancer in the Bevacizumab Era: A Population-based Analysis. <i>Clinical Colorectal Cancer</i> , 2011, 10, 97-101.	1.0	26
67	Adjuvant Chemotherapy for Stage III Colon Cancer: Does Timing Matter?. <i>Diseases of the Colon and Rectum</i> , 2011, 54, 1082-1089.	0.7	47
68	Evaluation of Guanylyl Cyclase C Lymph Node Status for Colon Cancer Staging and Prognosis. <i>Annals of Surgical Oncology</i> , 2011, 18, 3261-3270.	0.7	30
69	Presentation and outcomes of patients aged 30 years and younger with colorectal cancer: a 20-year retrospective review. <i>Medical Oncology</i> , 2011, 28, 1058-1061.	1.2	21
70	Prognostic web-based models for stage II and III colon cancer. <i>Cancer</i> , 2011, 117, 4155-4165.	2.0	25
71	Validation of predictive models for germline mutations in DNA mismatch repair genes in colorectal cancer. <i>International Journal of Cancer</i> , 2010, 126, 930-939.	2.3	35
72	Primary Tumor Resection in Patients Presenting With Metastatic Colorectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 52-55.	0.6	26

#	ARTICLE	IF	CITATIONS
73	Adjuvant Chemotherapy for Resected Stage II and III Colon Cancer: Comparison of Two Widely Used Prognostic Calculators. <i>Seminars in Oncology</i> , 2010, 37, 39-46.	0.8	21
74	Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2231-2237.	0.8	611
75	Impact of Irinotecan and Oxaliplatin on Overall Survival in Patients With Metastatic Colorectal Cancer: A Population-Based Study. <i>Journal of Oncology Practice</i> , 2009, 5, 153-158.	2.5	13
76	Cetuximab, chemotherapy and KRAS status in mCRC. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 379-380.	12.5	8
77	Evolving end points for clinical trials in advanced colorectal cancer. <i>Current Colorectal Cancer Reports</i> , 2009, 5, 135-139.	1.0	1
78	Intraperitoneal Treatment for Peritoneal Mucinous Carcinomatosis of Appendiceal Origin After Operative Management. <i>Annals of Surgery</i> , 2009, 249, 588-595.	2.1	17
79	A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168). <i>Investigational New Drugs</i> , 2008, 26, 265-272.	1.2	60
80	Individual data pooled analyses to improve understanding of adjuvant therapy in colon cancer: Review of the ACCENT collaborative group. <i>Current Colorectal Cancer Reports</i> , 2008, 4, 155-159.	1.0	1
81	Patterns of Diagnosis for Colorectal Cancer: Screening Detected vs. Symptomatic Presentation. <i>Diseases of the Colon and Rectum</i> , 2008, 51, 573-577.	0.7	10
82	Trends in Chemotherapy Utilization for Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2008, 7, 386-389.	1.0	24
83	Adjuvant Therapy with Raltitrexed in Patients with Colorectal Cancer Intolerant of 5-Fluorouracil: British Columbia Cancer Agency Experience. <i>Cancer Investigation</i> , 2007, 25, 711-714.	0.6	14
84	Colorectal Cancer. <i>Mayo Clinic Proceedings</i> , 2007, 82, 114-129.	1.4	55
85	Capecitabine-Induced Cerebellar Toxicity. <i>Clinical Colorectal Cancer</i> , 2006, 6, 70-71.	1.0	32
86	Hepatic Dysfunction During and After Lymphoma Chemotherapy in Patients With Hepatitis C. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, 636-638.	1.1	1
87	End Points for Adjuvant Therapy Trials: Has the Time Come to Accept Disease-Free Survival as a Surrogate End Point for Overall Survival?. <i>Oncologist</i> , 2006, 11, 624-629.	1.9	66
88	Colorectal cancer prevention: Is an ounce of prevention worth a pound of cure?. <i>Seminars in Oncology</i> , 2005, 32, 24-34.	0.8	49
89	New developments in therapy for metastatic colorectal cancer. <i>Current Colorectal Cancer Reports</i> , 2005, 1, 13-17.	1.0	0
90	Isolated Loss of PMS2 Expression in Colorectal Cancers: Frequency, Patient Age, and Familial Aggregation. <i>Clinical Cancer Research</i> , 2005, 11, 6466-6471.	3.2	54

#	ARTICLE	IF	CITATIONS
91	Duration of adjuvant therapy for colorectal cancer: are we overtreating our patients?. <i>Nature Clinical Practice Oncology</i> , 2005, 2, 276-277.	4.3	0
92	Outcomes in Elderly Patients with Advanced Colorectal Cancer Treated with Capecitabine: A Population-Based Analysis. <i>Clinical Colorectal Cancer</i> , 2005, 5, 279-282.	1.0	38
93	Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much?. <i>Journal of Clinical Oncology</i> , 2004, 22, 1797-1806.	0.8	913
94	Role of cyclooxygenase-2 in colorectal cancer. <i>Cancer and Metastasis Reviews</i> , 2004, 23, 63-75.	2.7	163
95	First-Line Treatment Strategies to Improve Survival in Patients with Advanced Colorectal Cancer. <i>Drugs</i> , 2004, 64, 27-44.	4.9	21
96	New targeted therapies in gastrointestinal cancers. <i>Current Treatment Options in Oncology</i> , 2003, 4, 393-403.	1.3	20
97	New developments in therapy for colorectal cancer. <i>Current Oncology Reports</i> , 2003, 5, 183-191.	1.8	5
98	Use of random skin biopsy to diagnose intravascular lymphoma presenting as fever of unknown origin. <i>American Journal of Medicine</i> , 2003, 114, 56-58.	0.6	71
99	Asian Ethnicity-Related Differences in Gastric Cancer Presentation and Outcome Among Patients Treated at a Canadian Cancer Center. <i>Journal of Clinical Oncology</i> , 2003, 21, 2070-2076.	0.8	124
100	Paraneoplastic Sensory Neuronopathy and Spontaneous Regression of Small Cell Lung Cancer. <i>Canadian Journal of Neurological Sciences</i> , 2003, 30, 269-271.	0.3	54
101	Massive Bleeding on a Bladder Protectant. <i>Archives of Internal Medicine</i> , 2002, 162, 1644.	4.3	8
102	Obstacles to Residents' Conducting Research and Predictors of Publication. <i>Academic Medicine</i> , 2001, 76, 477.	0.8	65